Low Dose Naltrexone
Cross-source consensus on Low Dose Naltrexone from 1 sources and 8 claims.
1 sources · 8 claims
How it works
Benefits
Dosage & preparation
Preparation
Risks & contraindications
Highlighted claims
- LDN must be compounded because it is not commercially manufactured at therapeutic low doses, and quality varies significantly between pharmacies. — Low Dose Naltrexone: Menopause, Autoimmune Disease, and Inflammatory Modulation
- Concurrent opioid use is an absolute contraindication for LDN; patients must be fully opioid-free before initiating treatment. — Low Dose Naltrexone: Menopause, Autoimmune Disease, and Inflammatory Modulation
- At low doses of 0.5–4.5 mg, naltrexone produces fundamentally different effects than standard doses through the principle of hormesis. — Low Dose Naltrexone: Menopause, Autoimmune Disease, and Inflammatory Modulation
- LDN intermittently blocks opioid receptors rather than sustaining blockade, triggering a biofeedback response that upregulates endogenous opioid production. — Low Dose Naltrexone: Menopause, Autoimmune Disease, and Inflammatory Modulation
- Vivid dreams are the most commonly reported side effect of LDN, are dose-dependent, and resolve with dose reduction. — Low Dose Naltrexone: Menopause, Autoimmune Disease, and Inflammatory Modulation
- LDN's primary mechanism for reducing excess cytokine production involves TLR4 blockade while preserving functional immune response. — Low Dose Naltrexone: Menopause, Autoimmune Disease, and Inflammatory Modulation
- LDN has an exceptionally favorable long-term safety profile with minimal adverse effects outside the opioid contraindication. — Low Dose Naltrexone: Menopause, Autoimmune Disease, and Inflammatory Modulation
- Full benefit from LDN requires 6 months to 2 years; early discontinuation is discouraged. — Low Dose Naltrexone: Menopause, Autoimmune Disease, and Inflammatory Modulation